Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome

Courtney D. DiNardo, Gail J. Roboz, Justin M. Watts, Yazan F. Madanat, Gabrielle T. Prince, Praneeth Baratam, Stéphane de Botton, Anthony Stein, James M. Foran, Martha L. Arellano, David A. Sallman, Mohammad Hossain, Dylan M. Marchione, Xiaofei Bai, Prapti A. Patel, Stephanie M. Kapsalis, Guillermo Garcia-Manero, Amir T. Fathi

Blood Adv (2024) 8 (15): 4209–4220.

https://doi.org/10.1182/bloodadvances.2023012302

Published: 2024

Includes: Supplemental data

Journal Articles

Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm

Alex Bataller, Georgina Gener-Ricos, Emmanuel Almanza-Huante, Kelly S. Chien, Samuel Urrutia, Alexandre Bazinet, Juan Jose Rodriguez-Sevilla, Danielle Hammond, Koji Sasaki, Koichi Takahashi, Courtney D. DiNardo, Farhad Ravandi, Gautam Borthakur, Tapan M. Kadia, Rashmi Kanagal-Shamanna, Hagop M. Kantarjian, Guillermo Garcia-Manero, Guillermo Montalban-Bravo

Blood Adv (2024) 8 (11): 2695–2706.

https://doi.org/10.1182/bloodadvances.2024012565

Published: 2024

Includes: Supplemental data

Journal Articles

Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax

Alex Bataller, Alexandre Bazinet, Courtney D. DiNardo, Abhishek Maiti, Gautam Borthakur, Naval G. Daver, Nicholas J. Short, Elias J. Jabbour, Ghayas C. Issa, Naveen Pemmaraju, Musa Yilmaz, Guillermo Montalban-Bravo, Koichi Takahashi, Sanam Loghavi, Guillermo Garcia-Manero, Farhad Ravandi, Hagop M. Kantarjian, Tapan M. Kadia

Blood Adv (2024) 8 (4): 927–935.

https://doi.org/10.1182/bloodadvances.2023011757

Published: 2024

Includes: Supplemental data

Journal Articles

Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity

Blood Adv (2023) 7 (13): 3284–3296.

https://doi.org/10.1182/bloodadvances.2022009391

Published: 2023

Includes: Supplemental data

Journal Articles

Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2 -mutant myelodysplastic syndrome

Blood Adv (2023) 7 (11): 2378–2387.

https://doi.org/10.1182/bloodadvances.2022008378

Published: 2023

Includes: Supplemental data

Journal Articles

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML

Blood Adv (2023) 7 (6): 933–942.

https://doi.org/10.1182/bloodadvances.2022008316

Published: 2023

Includes: Supplemental data

Journal Articles

Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside–based low-intensity therapy

Sangeetha Venugopal, Gautam Borthakur, Naval Daver, Courtney D. DiNardo, Naveen Pemmaraju, Nicholas J. Short, Hussein A. Abbas, Guillermo Garcia-Manero, Marina Konopleva, Farhad Ravandi, Tapan M. Kadia

Blood Adv (2022) 6 (19): 5546–5549.

https://doi.org/10.1182/bloodadvances.2021006689

Published: 2022

Journal Articles

High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse

Blood Adv (2022) 6 (13): 4006–4014.

https://doi.org/10.1182/bloodadvances.2022007378

Published: 2022

Includes: Supplemental data

Journal Articles

Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD

Naveen Pemmaraju, Nathaniel R. Wilson, Guillermo Garcia-Manero, Koji Sasaki, Joseph D. Khoury, Nitin Jain, Gautam Borthakur, Farhad Ravandi, Naval Daver, Tapan Kadia, Courtney DiNardo, Elias Jabbour, Sherry Pierce, Muzaffar Qazilbash, Marina Konopleva, Hagop Kantarjian

Blood Adv (2022) 6 (10): 3027–3035.

https://doi.org/10.1182/bloodadvances.2021006645

Published: 2022

Includes: Supplemental data

Journal Articles

A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes

Amer M. Zeidan, Isaac Boss, C. L. Beach, Wilbert B. Copeland, Ethan Thompson, Brian A. Fox, Vanessa E. Hasle, Ken Ogasawara, James Cavenagh, Lewis R. Silverman, Maria Teresa Voso, Andrzej Hellmann, Mar Tormo, Tim O’Connor, Alessandro Previtali, Shelonitda Rose, Guillermo Garcia-Manero

Blood Adv (2022) 6 (7): 2207–2218.

https://doi.org/10.1182/bloodadvances.2021005487

Published: 2022

Includes: Supplemental data

Journal Articles

Outcomes of acute lymphoblastic leukemia with KMT2A ( MLL ) rearrangement: the MD Anderson experience

Guillaume Richard-Carpentier, Hagop M. Kantarjian, Guilin Tang, C. Cameron Yin, Joseph D. Khoury, Ghayas C. Issa, Fadi Haddad, Nitin Jain, Farhad Ravandi, Nicholas J. Short, Courtney D. DiNardo, Koichi Takahashi, Marina Y. Konopleva, Naval G. Daver, Tapan Kadia, Guillermo Garcia-Manero, Rebecca Garris, Susan O’Brien, Elias Jabbour

Blood Adv (2021) 5 (23): 5415–5419.

https://doi.org/10.1182/bloodadvances.2021004580

Published: 2021

Journal Articles

Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to anti–PD-1–based therapy

Hussein A. Abbas, Zoe Alaniz, Sean Mackay, Matthew Cyr, Jing Zhou, Ghayas C. Issa, Mansour Alfayez, Jairo Matthews, Steven M. Kornblau, Elias Jabbour, Guillermo Garcia-Manero, Marina Konopleva, Michael Andreeff, Naval Daver

Blood Adv (2021) 5 (22): 4569–4574.

https://doi.org/10.1182/bloodadvances.2021004583

Published: 2021

Includes: Supplemental data

Journal Articles

Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis

Blood Adv (2021) 5 (16): 3163–3173.

https://doi.org/10.1182/bloodadvances.2020003829

Published: 2021

Journal Articles

Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax

Blood Adv (2021) 5 (8): 2173–2183.

https://doi.org/10.1182/bloodadvances.2020004173

Published: 2021

Includes: Supplemental data

Journal Articles

Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia

Blood Adv (2021) 5 (7): 1876–1883.

https://doi.org/10.1182/bloodadvances.2020003717

Published: 2021

Includes: Supplemental data

Journal Articles

Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia

Nicholas J. Short, Guillermo Montalban-Bravo, Hyunsoo Hwang, Jing Ning, Miguel J. Franquiz, Rashmi Kanagal-Shamanna, Keyur P. Patel, Courtney D. DiNardo, Farhad Ravandi, Guillermo Garcia-Manero, Koichi Takahashi, Marina Konopleva, Naval Daver, Ghayas C. Issa, Michael Andreeff, Hagop Kantarjian, Tapan M. Kadia

Blood Adv (2020) 4 (22): 5681–5689.

https://doi.org/10.1182/bloodadvances.2020003120

Published: 2020

Includes: Supplemental data

Journal Articles

A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients

Betül Oran, Marcos de Lima, Guillermo Garcia-Manero, Peter F. Thall, Ruitao Lin, Uday Popat, Amin M. Alousi, Chitra Hosing, Sergio Giralt, Gabriela Rondon, Glenda Woodworth, Richard E. Champlin

Blood Adv (2020) 4 (21): 5580–5588.

https://doi.org/10.1182/bloodadvances.2020002544

Published: 2020

Journal Articles

Clinical value of event-free survival in acute myeloid leukemia

Blood Adv (2020) 4 (8): 1690–1699.

https://doi.org/10.1182/bloodadvances.2019001150

Published: 2020

Includes: Supplemental data

Journal Articles

Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia

Blood Adv (2020) 4 (8): 1670–1677.

https://doi.org/10.1182/bloodadvances.2019001156

Published: 2020

Includes: Supplemental data

Journal Articles

Genomic context and TP53 allele frequency define clinical outcomes in TP53 -mutated myelodysplastic syndromes

Blood Adv (2020) 4 (3): 482–495.

https://doi.org/10.1182/bloodadvances.2019001101

Published: 2020

Includes: Supplemental data

NARROW

Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome

Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm

Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax

Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity

Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2 -mutant myelodysplastic syndrome

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML

Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside–based low-intensity therapy

High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse

Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD

A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes

Outcomes of acute lymphoblastic leukemia with KMT2A ( MLL ) rearrangement: the MD Anderson experience

Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to anti–PD-1–based therapy

Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis

Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax

Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia

Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia

A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients

Clinical value of event-free survival in acute myeloid leukemia

Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia

Genomic context and TP53 allele frequency define clinical outcomes in TP53 -mutated myelodysplastic syndromes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only